The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: Any difference?

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 4, 2004, Pages 473-476

  Selvarajan, S ^a   Bay, B H ^a   Chng, M J ^b   Tan, Puay Hoon ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Cost; Fluorescence in situ hybridisation; Overexpression

Indexed keywords

A0485; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MEMBRANE PROTEIN; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY A0485; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL CYCLE; CELL DIFFERENTIATION; CHROMOSOME 17Q; CLINICAL ARTICLE; DIAGNOSTIC KIT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HERCEP TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LABORATORY TEST; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTO ONCOGENE;

EID: 4644295843     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Lian SC, Tan PH. CerbB2 status in breast cancer: pathologic issues. Ann Acad Med Singapore 2002;31:793-8.
2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
3. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mod Pathol 1999;12:827-34.
4. Ceccarelli C, Santini D, Chieco P, Taffurelli M, Marrano D, Mancini AM. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour. Ann Oncol 1995;6:275-82.
5. Yokota T, Imamura M, Teshima S, Suzuki H, Tezuka F, Kikuchi S, et al. C-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study. Anticancer Res 1999;19:4007-12.
6. Mittra I, Redkar AA, Badwe RA. Prognosis of breast cancer: evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes. J Surg Oncol 1995;60:106-11.
7. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-9.
8. Agrup M, Stal O, Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000;63:23-9.
9. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-7.
10. Graziano C. HER-2 breast assay, linked to Herceptin wins FDA's okay. CAP Today 1998;12:13-6.
11. Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, et al. Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest™ in breast carcinoma by image analysis. Pathol Int 2001;51:33-6.
12. DAKO HercepTest™ for Immunoenzymatic Staining (1999) (Package insert) DAKO A/S, Glastrup, Denmark.
13. Fleiss JG. Statistical Methods for Rates and Proportions. New York: Wiley; 1981:225-32.
14. Landis JR, Koch GG. The measurement of observed agreement for categorical data. Biometrics 1977;33:159-74.
15. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-45.
16. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14:1079-86.
17. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
18. Selvarajan S, Bay BH, Choo A, Chuah KL, Sivaswaren CR, Tien SL, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem 2002;50:1693-6.
19. Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol 2000;113:251-8.
20. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-105.